Keywords: سانیتینیب; Dental implants; Targeted chemotherapy; Anti-angiogenesis; Sunitinib; Osseointegration; Micro-computed tomography; Histomorphometry;
مقالات ISI سانیتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سانیتینیب; Magnetic-MWCNT nanoparticles; Dispersive solid-liquid phase microextraction; Sunitinib; Honey; Human samples;
Keywords: سانیتینیب; Cardiopulmonary remodeling; Imatinib; Sunitinib; Pulmonary arterial hypertension;
Keywords: سانیتینیب; ASK1; apoptosis signal-regulating kinase 1; ASK2; apoptosis signal-regulating kinase 2; DMSO; dimethyl sulphoxide; hERG; human ether-a-go-go-related gene; JNK; c-Jun N-terminal kinase; MKK7; mitogen activated kinase kinase 7; MTT; 3-(4,5-dimethylthiazol-2
Keywords: سانیتینیب; Everolimus; Medical treatment; Surgery; Peptide receptor radionuclide therapy; Somatostatin receptor ligands; Sunitinib; Telotristat etiprate; Theranostics;
Keywords: سانیتینیب; Dalteparin; LMWH; Renal cell carcinoma; Sunitinib; VEGF;
Keywords: سانیتینیب; DEB(s); drug-eluting bead(s); TACE; transarterial chemoembolization; MALDI-SRM/MSI; matrix-assisted laser desorption ionization with selected reaction monitoring mass spectrometry imaging; FITC; Fluorescein isothiocyanate; LC-MS/MS; liquid chromatography
Keywords: سانیتینیب; Renal cell cancer; Management; Adjuvant; Sunitinib; Sorafenib; Guidelines;
Keywords: سانیتینیب; Cardiotoxicity; Heart failure; Radiation therapy; Sunitinib; Toxicity;
Keywords: سانیتینیب; Clear cell renal cell carcinoma; Sunitinib; Prognostic; Hilar fat infiltration;
Keywords: سانیتینیب; Antineoplastic agents/adverse effects; Angiogenesis inhibitors; Cardiotoxins; Vascular endothelial growth factor; Bevacizumab; Sorafenib; Sunitinib; Vandetanib; Aflibercept;
Keywords: سانیتینیب; Diabetes; Kidney cancer; Prognosis; Sunitinib; Targeted therapy;
Keywords: سانیتینیب; Heterogeneity; Intermediate prognosis; Metastatic renal cell carcinoma; Sunitinib;
Keywords: سانیتینیب; Genomic biomarker; Kidney cancer; Targeted therapy; Everolimus; Sunitinib; Tumor suppressor gene; PBRM1; SETD2; BAP1; KDM5C;
Keywords: سانیتینیب; Non-clear cell renal cell carcinoma; Papillary; Chromophobe; Sunitinib; Everolimus; Systematic review;
Keywords: سانیتینیب; cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: سانیتینیب; Gastrointestinal stromal tumor; GIST; Gastric mass; Abdominal tumor; Tyrosine kinase inhibitor; TKIs; Imatinib; Sunitinib;
Keywords: سانیتینیب; Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival;
Keywords: سانیتینیب; Pretreatment prealbumin; Prognosis; Renal cell carcinoma; Sorafenib; Sunitinib;
Keywords: سانیتینیب; MRONJ; Osteonecrosis; Bisphosphonates; Denosumab; Sunitinib;
Keywords: سانیتینیب; Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab;
Keywords: سانیتینیب; Hepatocellular cancer (HCC); Chemoimmunotherapy; Regulatory T cells (Tregs); Programmed cell death protein 1 (PD-1); Sunitinib; Cancer; Circulating tumor cell (CTC); Immune checkpoint;
Keywords: سانیتینیب; Cáncer renal metastásico; Sunitinib; Respuesta completa; Inhibidores de la tirosina cinasaMetastatic renal cell carcinoma; Sunitinib; Complete response; Tyrosine kinase inhibitors
Keywords: سانیتینیب; Gastrointestinal stromal tumor; Sunitinib; Tumor response criteria; RECIST; Choi
Keywords: سانیتینیب; Heart; Ionizing radiation; Sunitinib; Oxidative stress; Mitochondria;
Keywords: سانیتینیب; Metastatic Renal Cell Carcinoma; Metformin; Outcome; Sunitinib;
Keywords: سانیتینیب; Angiogenesis; ARC; Drug resistance; Renal cell carcinoma; Sunitinib
Keywords: سانیتینیب; Carcinoma; Renal cell; Sunitinib; Pazopanib; Vascular endothelial growth factor receptor;
Keywords: سانیتینیب; First-line mRCC treatment; mRCC prescribing preferences; Pazopanib; Sunitinib; TKI;
Keywords: سانیتینیب; Renal cell carcinoma; Sunitinib; Renal dysfunction; Antitumor efficacy;
Keywords: سانیتینیب; Intramuscular; Long-acting; Paliperidone palmitate; Clodronate; Sunitinib; Flip-flop PK
Keywords: سانیتینیب; Pancreatic neuroendocrine tumor; Somatostatin analogue; mTOR; Everolimus; Sunitinib; Temozolomide;
Keywords: سانیتینیب; Neuroendocrine tumors; Pancreatic neuroendocrine tumors; Carcinoid tumors; Octreotide; Lanreotide; Sunitinib; Everolimus;
Keywords: سانیتینیب; Antiangiogenic effect; Direct visualization; Flare-up; Renal cell carcinoma; Sunitinib;
Keywords: سانیتینیب; TKI, tyrosine kinase inhibitor; RTK, receptor tyrosine kinase; NRVM, neonatal rat ventricular myocyte; LVID;s, left ventricular interior diameter during systole; LV Vol;s, left ventricular volume during systoleGenistein; Sunitinib; Tyrosine kinase inhibit
Keywords: سانیتینیب; mRCC; sorafenib; sunitinib; thyroid function; TKI;
Keywords: سانیتینیب; Pazopanib; Sunitinib; Metastatic renal cell carcinoma (mRCC); Tumor flare; Growth rate; Treatment cessation; Treatment discontinuation; Tyrosine kinase inhibitors;
Keywords: سانیتینیب; Late recurrence; Prognostic factor; Renal cell carcinoma; Sunitinib; Survival
Keywords: سانیتینیب; Imaging; Pharmacokinetics; Renal cell cancer; Sunitinib; Toxicity
Keywords: سانیتینیب; Bevacizumab; Lapatinib; Sunitinib; Sorafenib; Rofecoxib; Celecoxib; Venlafaxine; Prednisone Licorice acid; cyclosporin A; Medications; Drug-induced hypertension; Blood pressure; chemicals; Tyrosine kinase inhibitors;
Keywords: سانیتینیب; Breast cancer; Relapse biopsy; Positron emission tomography; Hypoxia; Sunitinib;
Keywords: سانیتینیب; EGFR; ACC; Sunitinib; Erlotinib;
Keywords: سانیتینیب; Connexin; Mesothelioma; Chemotherapy; Sunitinib; Drug resistance
Keywords: سانیتینیب; Embolization; Anti-angiogenic; Gelling solution; Arteriovenous malformation; Sunitinib;
Keywords: سانیتینیب; Chronic stress; Norepinephrine; Adrenoceptor; Anti-angiogenic therapy; Sunitinib;
Keywords: سانیتینیب; Performance status; Renal cell carcinoma; Risk-directed treatment; Sarcomatoid differentiation; Sunitinib
Keywords: سانیتینیب; Brain metastases; Clinical trial; Renal cell carcinoma; Sunitinib
Keywords: سانیتینیب; Sunitinib; Diabetes; Pharmacokinetics; Hypoglycaemia; Rabbits
Keywords: سانیتینیب; Renal cell carcinoma; Sunitinib; Resistance; Matrix metalloproteinase; Tissue inhibitor of metalloproteinases;
Keywords: سانیتینیب; Antiangiogenic agents; Metastatic renal cells cancer; Complete response; Sunitinib; Sorafenib; Pazopanib; Bevacizumab; Cytokines; Interferon;